AN4005
Advanced Solid Tumors
PreclinicalIND-enabling
Key Facts
About Adlai Nortye
Adlai Nortye is a Cayman Islands-incorporated, China and US-based biotech company dedicated to discovering and developing novel anti-cancer treatments. Its strategy centers on advancing buparlisib, a drug with a history in other cancers, into a new pivotal indication (HNSCC) while building a broader pipeline targeting the tumor microenvironment. The company went public on the NASDAQ in 2023, raising capital to fund its late-stage clinical development and expand its research efforts.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| SHR-1701 | Jiangsu Hengrui Medicine | Phase 1 |
| BAY 1895344 | Bayer | Phase 1 |
| HS-10342 | Hansoh Pharma | Phase 1/2 |
| ANKTIVA® + M-ceNK | ImmunityBio | Phase 1 |
| DFTX-101 | Definium Therapeutics | Phase 1/2 |
| REC-617 | Recursion Pharmaceuticals | Phase 1/2 |
| ZW220 | Zymeworks | Preclinical |
| NX-1607 | Nurix Therapeutics | Phase 1a |
| IMA402 (TCR Bispecific) | Immatics | Phase 1 |
| IMA403 (TCR Bispecific) | Immatics | Pre-clinical |
| BCA101 | Bicara Therapeutics | Phase 1 |
| AN3025 | Adlai Nortye | Preclinical |